CDKN2A and neoplasm: In addition, DNA methylation analyses and full molecular reclassification according to the WHO 2021 classification including CDKN2A/B status were only feasible in a subset of patients given the limited availability of FFPE tissue, and low cellularity in tumor samples with resulting low yields of tumor DNA may compromise the validity of methylation profiles.